207 related articles for article (PubMed ID: 9527063)
1. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker.
Goydos JS; Brumfield AM; Frezza E; Booth A; Lotze MT; Carty SE
Ann Surg; 1998 Mar; 227(3):398-404. PubMed ID: 9527063
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy.
Cheon YK; Cho YD; Moon JH; Jang JY; Kim YS; Kim YS; Lee MS; Lee JS; Shim CS
Am J Gastroenterol; 2007 Oct; 102(10):2164-70. PubMed ID: 17617204
[TBL] [Abstract][Full Text] [Related]
3. Targeting IL-6 in cholangiocarcinoma therapy.
Mott JL; Gores GJ
Am J Gastroenterol; 2007 Oct; 102(10):2171-2. PubMed ID: 17897336
[TBL] [Abstract][Full Text] [Related]
4. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma.
Tangkijvanich P; Thong-ngam D; Theamboonlers A; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
Hepatogastroenterology; 2004; 51(55):15-9. PubMed ID: 15011822
[TBL] [Abstract][Full Text] [Related]
6. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
[TBL] [Abstract][Full Text] [Related]
7. High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study.
Jo JH; Chung MJ; Park JY; Bang S; Park SW; Kim KS; Lee WJ; Song SY; Chung JB
Surg Endosc; 2013 Nov; 27(11):4210-6. PubMed ID: 23760942
[TBL] [Abstract][Full Text] [Related]
8. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma.
Liu L; Wang J; Liu B; Dai S; Wang X; Chen J; Huang L; Xiao X; He D
J Cell Biochem; 2008 Jun; 104(3):745-55. PubMed ID: 18275060
[TBL] [Abstract][Full Text] [Related]
10. Serum cathepsin B to cystatin C ratio as a potential marker for the diagnosis of cholangiocarcinoma.
Monsouvanh A; Proungvitaya T; Limpaiboon T; Wongkham C; Wongkham S; Luvira V; Proungvitaya S
Asian Pac J Cancer Prev; 2014; 15(21):9511-5. PubMed ID: 25422248
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG
World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma.
Loosen SH; Roderburg C; Kauertz KL; Pombeiro I; Leyh C; Benz F; Vucur M; Longerich T; Koch A; Braunschweig T; Ulmer TF; Heidenhain C; Tacke F; Binnebösel M; Schmeding M; Trautwein C; Neumann UP; Luedde T
J Hepatol; 2017 Oct; 67(4):749-757. PubMed ID: 28668580
[TBL] [Abstract][Full Text] [Related]
13. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Soluble Intercellular Adhesion Molecule-1 and Interleukin-6 in Patients with Extrahepatic Cholangiocarcinoma.
Shimura T; Shibata M; Gonda K; Kofunato Y; Okada R; Ishigame T; Kimura T; Kenjo A; Marubashi S; Kono K; Takenoshita S
J Invest Surg; 2018 Dec; 31(6):475-482. PubMed ID: 28925763
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
[TBL] [Abstract][Full Text] [Related]
16. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
17. Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients.
Leelawat K; Leelawat S; Ratanachu-Ek T; Trubwongchareon S; Wannaprasert J; Tripongkaruna S; Chantawibul S; Tepaksorn P
World J Gastroenterol; 2006 Jul; 12(26):4195-8. PubMed ID: 16830373
[TBL] [Abstract][Full Text] [Related]
18. Analysis of new biomarkers for cholangiocarcinoma.
Miwa M; You G; Tanaka H; Taniguchi S; Fujii T; Kamemura K; Suzaki M; Isono T; Tooyama I; Tanaka M; Srivatanakul P; Viwatthanasittiphong C; Sangrajrang S; Khuhaprema T
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):397-8. PubMed ID: 24446393
[TBL] [Abstract][Full Text] [Related]
19. Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma.
Prakobwong S; Charoensuk L; Hiraku Y; Pinlaor P; Pairojkul C; Mairiang E; Sithithaworn P; Yongvanit P; Khuntikeo N; Pinlaor S
Int J Cancer; 2012 Aug; 131(4):E416-24. PubMed ID: 21935919
[TBL] [Abstract][Full Text] [Related]
20. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
